



Memo

Date:

May 13, 2022

To: Health care providers

From: Brian Ktytor, Chief Regional Officer, North East and North West
Anna Greenberg, Chief Regional Officer, Toronto and East
Susan deRyk, Chief Regional Officer, Central and West

CC: Dr. Chris Simpson, Executive Vice President, Medical
Mark Walton, Senior Vice President, COVID-19 Pandemic Response

Re: Access to Evusheld

On April 14, 2022, the prophylactic monoclonal antibody therapy Evusheld was authorized by Health Canada for the prevention of COVID-19 in immunocompromised adults and children 12 years of age and older. This memo is intended to inform health care providers about who can receive Evusheld and how to access it.

Who can receive Evusheld

The supply of Evusheld is currently limited in Canada. In Ontario, Evusheld will be administered to individuals with the highest risk of a severe outcome from COVID-19, including:

- solid organ transplant recipients;
- stem cell transplant recipients;
- CAR-T therapy recipients; and
- other hematologic cancer patients undergoing treatment.

As supply of Evusheld increases, eligibility may be expanded in order to ensure that those populations in most need of treatment have access.

Where is Evusheld available

Evusheld will be distributed to and administered by a number of clinics across the province that care for patients who are likely to be eligible, including cancer centres and transplant sites. Ontario Health regions are working to ensure pathways are in place so that all eligible patients can access Evusheld.

Care teams at cancer centres and transplant sites will be contacting eligible patients directly to offer Evusheld. Health care providers caring for patients who meet the criteria outlined above may direct eligible patients to contact their specialist to learn more about Evusheld.

Resources for health care providers who may be prescribing or administering Evusheld

Ontario Health has developed a toolkit to support health care providers who may be prescribing or administering Evusheld. This toolkit may also be of interest to other health care providers who are looking for more information about Evusheld.

The toolkit includes the following resources:

- [Information about Evusheld \(tixagevimab and cilgavimab\): Reference for health care providers who may be prescribing or administering Evusheld](#)
- [Patient handout on Evusheld](#)

Questions about how to access Evusheld may be directed to the Ontario Health regional contacts listed below. Thank you for your attention to this information and for your ongoing dedication to providing the best possible care for your patients.

Ontario Health regional contacts

| | |
|---------------------------|---|
| Central | Amy Khan (Amy.Khan@ontariohealth.ca) David Pearson (David.Pearson@ontariohealth.ca) |
| East | Farrah Hirji (Farrah.Hirji@ontariohealth.ca) Leah Bartlett (Leah.Bartlett@ontariohealth.ca) |
| Toronto | TOTherapeutics@ontariohealth.ca |
| West | Jennifer Mills Beaton (Jennifer.MillsBeaton@ontariohealth.ca) Karen Bell (Karen.M.Bell@ontariohealth.ca) |
| North East and North West | Jennifer MacKinnon (Jennifer.MacKinnon@ontariohealth.ca) |